In the large series by Couch et al. of 58,798 women with BC that were referred to hereditary cancer clinics, a mutation rate of 1.73% for CHEK2, 1.06% for ATM, and 0.87% for PALB2 were reported [28]. Here, CHEK2 is linked to hereditary cancer.